Table 1.
Demographic and clinical characteristics of the GR High and GR low breast cancer patients in METABRIC and TCGA in the entire cohort.
| Demographic and Clinical Characteristics | METABRIC | TCGA | ||||
|---|---|---|---|---|---|---|
| Clinical Variables (percent per GR status) | GR-LOW n = 348 |
GR-HIGH n = 348 |
p-value | GR-LOW n = 256 |
GR-HIGH n = 256 |
p-value |
| Age at diagnosis | 0.063 | 0.376 | ||||
| Median | 63 | 61 | 59 | 60 | ||
| IQR | 53–71 | 52–69 | 50–69 | 50–66 | ||
| Stage at diagnosis | 0.017 | 0.019 | ||||
| I | 104 (29.9%) | 140 (40.2%) | 36 (14.0%) | 56 (21.9%) | ||
| II | 215 (61.8%) | 182 (52.3%) | 165 (64.5%) | 135 (52.7%) | ||
| III | 29 (8.3%) | 26 (7.5%) | 55 (21.5%) | 65 (25.4%) | ||
| Clinical Subtypes | ||||||
| ER Positive | 257 (48.1%) | 277 (51.9%) | 0.088 | 183 (47.2%) | 205 (52.8%) | 0.020 |
| PR Positive | 188 (51.8%) | 175 (48.2%) | 0.363 | 152 (45%) | 186 (55%) | 0.001 |
| HER2 Positive | 59 (71.1%) | 24 (28.9%) | <0.001 | 54 (65.1%) | 29 (34.9%) | <0.001 |
| Triple Negative | 55 (49.1%) | 57 (50.9%) | 0.918 | 28 (65.1%) | 15 (34.9%) | 0.033 |
| PAM50 Subtypes | <0.001 | <0.001 | ||||
| Luminal A | 117 (33.6%) | 137 (39.4%) | 65 (25.4%) | 149 (58.2%) | ||
| Luminal B | 102 (29.3%) | 64 (18.4%) | 45 (17.6%) | 34 (13.3%) | ||
| HER2 | 59 (17%) | 24 (6.9%) | 21 (8.2%) | 7 (2.7%) | ||
| Basal | 57 (16.4%) | 47 (13.5%) | 30 (11.7%) | 27 (10.5%) | ||
Differences between GR-low and GR-high groups were tested for statistical significance using Fisher’s exact test. IQR = Interquartile range, HER2 = human epidermal growth factor receptor2.